» Articles » PMID: 12378511

Expression of G1-S Modulators (p53, P16, P27, Cyclin D1, Rb) and Smad4/Dpc4 in Intrahepatic Cholangiocarcinoma

Overview
Journal Hum Pathol
Specialty Pathology
Date 2002 Oct 16
PMID 12378511
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrations of G1-S cell cycle arrest and TGF-beta/Smad pathway are critical events in human carcinogenesis. We studied alterations of both pathways by immunohistochemical staining for p53, p16, p27, cyclin D1, Rb and Smad4/Dpc4 in 42 intrahepatic cholangiocarcinomas (ICCs). Abnormal nuclear overexpression of p53 and cyclin D1 was noted in 15 (35.7%) and 26 (61.9%) cases, respectively. Total loss of p16, p27, Rb and Smad4 was detected in 15 (35.7%), 13 (31.0%), 5 (11.9%) and 19 (45.2%) cases, respectively. Forty cases (95.2%) showed aberrations of at least one of the pathways, of which 21 (50%) revealed abnormality in G1-S pathway only, 17 (40.5%) had abnormalities in both pathways and 2 (4.8%) had an abnormality in TGF-beta/Smad pathway only. Among the examined genes, loss of Smad4 was found to have a positive relationship with the pTNM stage (P < 0.05). The overall stage of the high-altered group (alterations in 2 to 5 of the genes, n = 29) was significantly higher than that of the low-altered group (alteration of one or no gene, n = 13) (P < 0.01). We also examined the expression of above genes in the accompanying biliary dysplasia and found out abnormal expression of p53, cyclin D1 or p16 in 7 out of 13 dysplastic lesions. Our data suggest that abnormal G1-S cell cycle and altered TGF-beta/Smad pathway are major events in cholangiocarcinogenesis. Moreover, there might be a possible cumulative effect of the alterations in the examined genes upon the clinical outcome of patients with resectable ICCs.

Citing Articles

Ad6-Based GM-CSF Expressing Vector Displays Oncolytic and Immunostimulatory Effects in an Immunocompetent Syrian Hamster Model of Cholangiocarcinoma.

Zabelina D, Osipov I, Maslov D, Kovner A, Vasikhovskaia V, Demina D Viruses. 2025; 17(2).

PMID: 40006917 PMC: 11861176. DOI: 10.3390/v17020162.


Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.

Porreca V, Barbagallo C, Corbella E, Peres M, Stella M, Mignogna G Cancers (Basel). 2024; 16(16).

PMID: 39199659 PMC: 11352949. DOI: 10.3390/cancers16162889.


Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research.

Li M, Zhou X, Wang W, Ji B, Shao Y, Du Q J Clin Transl Hepatol. 2022; 10(4):700-710.

PMID: 36062286 PMC: 9396327. DOI: 10.14218/JCTH.2021.00374.


Associations of SMAD4 rs10502913 and NLRP3 rs1539019 Polymorphisms with Risk of Coal Workers' Pneumoconiosis Susceptibility in Chinese Han Population.

Zhao H, Huang Y, Wang H, Zhao J, Tian S, Bai H Pharmgenomics Pers Med. 2022; 15:167-175.

PMID: 35280939 PMC: 8904432. DOI: 10.2147/PGPM.S351658.


Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy.

Koustas E, Trifylli E, Sarantis P, Papavassiliou A, Karamouzis M World J Gastrointest Oncol. 2021; 13(10):1229-1243.

PMID: 34721764 PMC: 8529918. DOI: 10.4251/wjgo.v13.i10.1229.